Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Biomaterials. 2012 Sep;33(27):6495-506. doi: 10.1016/j.biomaterials.2012.05.039. Epub 2012 Jun 15.
Multidrug resistance (MDR) remains one of the main challenges in the successful chemotherapy of human cancer. RNA interference (RNAi) strategy aiming at only one cause of MDR was widely applied, nevertheless hardly obtained satisfactory tumor-suppressing effect. In this work, a new attempt to package two kinds of RNA with different functions into one vector and reverse MDR against two different mechanisms via RNAi was carried out. A new bioreducible poly (β-amino esters) (PAEs), poly[bis(2-hydroxylethyl)-disulfide-diacrylate-β-tetraethylenepentamine] (PAP) was synthesized by Michael addition reaction. The PAEs/RNA complex nanoparticles (PAEN) were prepared. The experimental results demonstrated that co-delivery of iMdr-1-shRNA and iSurvivin-shRNA could be achieved by a single vector, and interfering two genes simultaneously had a synergistic effect on overcoming MDR. PAEN lowered the IC(50) value of doxorubicin (DOX) in MDR tumor cells to a comparable level to that in the sensitive cell line through down-regulating the expression of P-gp and Survivin, and decreased the tumor volumes in mice xenograft model bearing DOX-resistant human breast cancer when combined with DOX. These results illustrated that PAEN could be applied as potential efficient non-viral RNA carriers for reversing MDR.
多药耐药(MDR)仍然是人类癌症化疗成功的主要挑战之一。针对 MDR 一个原因的 RNA 干扰(RNAi)策略被广泛应用,但几乎没有获得令人满意的肿瘤抑制效果。在这项工作中,我们进行了一项新的尝试,即将两种具有不同功能的 RNA 包装到一个载体中,并通过 RNAi 逆转两种不同机制的 MDR。一种新型生物可还原的聚(β-氨基酯)(PAE),聚[双(2-羟乙基)-二硫代二丙烯酸酯-β-四亚乙基五胺](PAP)通过迈克尔加成反应合成。制备了 PAE/RNA 复合纳米粒(PAEN)。实验结果表明,通过单个载体可以实现 iMdr-1-shRNA 和 iSurvivin-shRNA 的共递送,并且同时干扰两个基因对克服 MDR 具有协同作用。PAEN 通过下调 P-糖蛋白和 Survivin 的表达,将多柔比星(DOX)在多药耐药肿瘤细胞中的 IC(50)值降低到与敏感细胞系相当的水平,并与 DOX 联合降低了荷有 DOX 耐药人乳腺癌的小鼠异种移植模型中的肿瘤体积。这些结果表明,PAEN 可用作逆转 MDR 的潜在高效非病毒 RNA 载体。